Phase 4
Completed N=66
Magnesium Sulfate in Obese Preeclamptics
Source: ClinicalTrials.gov NCT02835339 ↗Enrolled (actual)
66
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: Maternal Serum Magnesium Level at 4 Hours After Administration — 3.53; 4.41 mg/dL
◆ Published Evidence
Established
20citations · ~3 / year
Alternate Dosing Protocol for Magnesium Sulfate in Obese Women With Preeclampsia: A Randomized Controlled Trial.
Summary
The purpose of this study is to learn how medications participant will receive in the course of their delivery are metabolized (broken down by the body). The investigators hope to learn more about the way drugs are metabolized by pregnant women, and how those drugs are distributed in the blood and body compartments and cleared in the urine, and how maternal body weight affects the metabolism. With this information the investigators will be able to develop a treatment regimen considering factors in the body that affect magnesium levels so that the investigators can improve treatment of pregnant women. The goal of the study is to understand how different dosing of magnesium sulfate affects blood levels of the magnesium in larger women.
Linked Publications (2)
-
Alternate Dosing Protocol for Magnesium Sulfate in Obese Women With Preeclampsia: A Randomized Controlled Trial.
-
Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maternal Serum Magnesium Level at 4 Hours After Administration |
3.53; 4.41 | — |
| SECONDARY Maternal Serum Magnesium Level at Time of Delivery |
3.73; 5.44 | — |
| SECONDARY Maternal Side Effects |
5.5; 10.5; 0; 5.2; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Pregnant women who are ages 18-45
- 32-42 weeks' pregnant
- Prescribed magnesium sulfate for preeclampsia
- BMI ≥35 kg/m2
Exclusion Criteria
- Pregnant women < 32 weeks' pregnant
- Women who are on dialysis
Data sourced from ClinicalTrials.gov (NCT02835339) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.